Burkholderia in Healthcare Environments Exposed in New Online Video
The IAQ Video Network produces another educational video about environmental dangers due to exposure to microbial pathogens and environmental hazards.
Phoenix, AZ, November 14th, 2011 -- Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses the threat to human health due to Burkholderia cepacia in healthcare environments.
Burkholderia cepacia is the name of a group or “complex” of bacteria that can be found in soil and water and survive for extended periods of time in moist environments. Also known as BCC or B. cepacia, the bacteria are often resistant to common antibiotics.
“Burkholderia cepacia poses little medical risk to most healthy people,” reported Paul Cochrane, President of Cochrane and Associates, the company behind the IAQ Video Network and the new public outreach video. “However, people who have certain health problems like weakened immune systems or chronic lung diseases, particularly cystic fibrosis, may be more susceptible to infections from Burkholderia cepacia. We hope this new online video helps to educate people about these dangerous bacteria and ways people can protect their health.”
To view this video please visit http://www.iaqtv.com/ or
http://www.youtube.com/watch?v=Vf6f5cC2WK8
To learn more please visit http://www.cochraneassoc.com/, email info@cochraneassoc.com or call (602)510-3179.
About Cochrane & Associates, LLC & the IAQ Video Network
Cochrane & Associates is a business development, public relations and marketing consulting firm that specializes in the environmental, HVAC, mold and indoor air quality industries. The company has worked with many of the industries’ leading institutions and companies and continues to be an innovator in the industry. They are also the innovators behind the IAQ Video Network.
-
Most popular related searches
Related news
-
SeqOne Genomics closes €20M series A to accelerate the deployment of its genomic medicine platform
The round, led by Omnes, Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease. The company will intensify investments in the development of its genomic-aware data lake to...
-
Daxor Corporation to Commence Trading on the Nasdaq Capital Market
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange – American. Daxor’s common stock will continue trading under the ticker symbol “DXR” after the transfer. The Company’s common stock will continue to trade on the NYSE American until the...
-
The Indoor Microbiome and Its Impact on Indoor Environmental Quality
Last year, the U.S. Environmental Protection Agency (EPA) announced the release of a new webpage to provide information about the indoor microbiome. All of the living microorganisms inside of an indoor environment, and their by-products, are collectively known as the indoor microbiome. The indoor microbiome that surrounds each of us is diverse and dynamic, made up of bacteria, viruses, fungi and other single-celled organisms. These microorganisms may be growing or inactive, and may be present in different life...
-
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022. Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100® next generation development. The presentation will be available on-demand beginning at 7:00 a.m. ET...
-
Daxor Announces Key Milestones Achieved for Multicenter BVA-100 Study in Hospitalized Patients With COVID-19
Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces patient enrollment is complete and data analysis is underway in preparation for publication of the multi-center observational prospective study utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology in hospitalized COVID-19 patients. NYU Langone Health, Wake Forest School of Medicine and OHSU have been enrolling subjects since the onset of the pandemic. Dr. Jan Bakker, MD,...
Customer comments
No comments were found for Burkholderia in Healthcare Environments Exposed in New Online Video. Be the first to comment!